Telehealth companies have carved out an unusual position in the obesity drug market — offering lifestyle coaching to help patients on medications like GLP-1s lose weight, while simultaneously fielding pressure from employers to keep a lid on what those drugs cost.
The tension, reported by NPR on Saturday, June 14, 2026, cuts to the heart of how Americans actually get access to weight-loss drugs. Insurers and self-funded employers increasingly contract with telehealth platforms to manage obesity treatment programs. That gives those platforms real power over what gets prescribed, what gets covered, and how long someone stays on a medication.
On one side of that equation, the lifestyle support piece makes clinical sense. People on obesity drugs tend to see better outcomes when they also get behavioral coaching — dietary guidance, check-ins, accountability. Telehealth companies have built programs around exactly that.
On the other side: cost. Drugs like semaglutide carry list prices that can run into hundreds of dollars per month, and employers footing insurance bills want someone watching the spending. Telehealth providers, it turns out, are the ones getting that call.
That dual role raises a question the source doesn’t fully answer — whether a telehealth company told to limit drug spending can also serve as a neutral advocate for the patient trying to get that drug covered. The two goals don’t always point the same direction.
NPR did not detail specific contracts, dollar thresholds, or named telehealth companies in the portion of the story available. What it does describe is a structural arrangement that’s become common enough to warrant scrutiny: the same company helping you lose weight is also helping your employer spend less on the drugs that make weight loss possible.
Whether patients are being told about that arrangement when they sign up isn’t clear from the reporting.
Reported by NPR. Read the original report.
